Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome

Transfusion and Apheresis Science

Volumn 28, Issue 2, 2003, Pages 117-124

  Chamouni, P ^a   Tamion, F ^b   Gueit, I ^b   Girault, C ^b   Lenain, P ^c   Varin, R ^b   Czernichow, P ^b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

^c CENTRE HENRI BECQUEREL   (France)

Author keywords

ABO blood group system; Guillain Barre syndrome; Hemolytic anaemia; Intravenous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; GUILLAIN BARRE SYNDROME; HEMOLYTIC ANEMIA; HUMAN;

EID: 0037383886     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00012-0     Document Type: Article

References (40)

1. Raphael J.C., Chevret S., Auriant I., Sharshar T., Bouget J., Bolgert F. Treatment of the adult Guillain-Barre syndrome: indications for plasma exchange. Transfus. Sci. 20(1):1999;53-61.
2. Raphael J.C., Sharshar T. Guillain-Barre syndrome: epidemiological, clinical and therapeutic insight. Ann. Med. Interne (Paris). 151(Suppl 1):2000;1S35-1S40.
3. Ben Ghorbel I., Louzir B., Othmani S., Boussema E., M'Saddek F., Bahri M., Battikh R., Bahri M. Polyradiculoneuropathy in systemic lupus erythematosus. Beneficial effect of intravenous immunoglobulin therapy. Report of a case. Semaine des Hopitaux. 74(23-26):1998;994-996.
4. LoVecchio F., Jacobson S. Approach to generalized weakness and peripheral neuromuscular disease. Emergency Med. Clinics North Am. 15/3:1997;605-623.
5. Vallat J.M., Tabaraud F. Neuropathies périphériques. Encyclopedia Medicine Chir, Neurologie. 1997;. 17-100-A-10;1997, 18pp.
6. Raphael J.C.et al. Prise en charge des patients atteints d'un syndrome de Guillain-Barréde l'adulte proposition d'une stratégiethérapeutique. Ream Urg. 7:1998;571-579.
7. Asbury A.K.et al. The inflammatory lesions in idiopathic polyneuritis. Medecine. 48:1969;173-215.
8. Ropper A.H., Wijdicks E.F.M., Truax B.T. Differential diagnosis Guillain-Barre syndrome. Contemporary neurology series. 1991;Davis Company, Philadelphia.
9. Van Der Meche F.G.A., Schmitz P.I.M., the Dutch Guillain-Barre study group A randomized trial comparing intravenous immune globine and plasma exchange in Guillain-Barre syndrome. N. Engl. J. Med. 326:1992;1123-1129.
10. French Cooperative Group on plasma exchange in Guillain-Barre syndrome Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann. Neurol. 41:1997;298-306.
11. Yu Z., Lennon V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. New Engl. J. Med. 340:1999;227-228.
12. ® [0.5 G/10 ml-2.5 g/50ml-5g/100 ml-10 g/200 ml]. Laboratoire Français du Fractionnement et des biotechnologies. France January 2000.
13. Wilson J.R., Bhoopalam H., Fisher M. Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve. 20(9):1997;1142-1145.
14. Mouthon L., Kaveri S.V., Spalther S.H., Lacroix-Desmazes S., Lefranc C.et al. Mecanisms of action of intravenous immune globulin in immune-mediated diseases. Clin. Exp. Immunol. 104(suppl 1):1996;3-9.
15. Kazatchkine M.D., Dietrich G., Hurez V., Ronda N., Bellon B., Rossi F.et al. V region-mediated selection of autorective repertoires by intravenous immunoglobulin (IgIV). Immunol. Rev. 139:1994;79-107.
16. Lacroix-Desmazes S., Kaveri S.V., Kazatchkine M.D. Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins. Rev. Neurol. 152(5):1996;349-354.
17. Kaveri S.V.et al. Modulation of autoimmune response by intravenous immunoglobulin (IgIV). Mult. Scler. 3(2):1997;121-128.
18. Dwyer J.M. Manipulating the immune system with the immune globulin. N. Engl. J. Med. 326(2):1992;107-108.
19. Plasma exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 349:1997;225-230.
20. Bussel A., Boulechfar H., Naim R. Synchronizing intravenous polyvalent gammaglobulins and plasma exchange. A study of 11 patients. Annales de Medecine Interne. 144/8:1993;532-538.
21. Ronda N., Haury M., Nobrega A., Coutinho A., Kazatchkine M.D. Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IgIV). Clin. Immunopathol. 70:1994;124-128.
22. Dietrich G., Algiman M., Sultan Y., Nydegger U.E., Kazatchkine M.D. Origin of anti-idiotypic activity against anti factor VIII autoantibodies in pools of normal human immunoglobulin G (IgIV). Blood. 79:1992;2946-2951.
23. Van Doorn P.A., Rossi F., Brand A., Van Lint M., Vermeulen M., Kazatchkine M.D. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 29(1-3):1990;57-64.
24. Okubo S., Ishida T., Yasunaga K. Hemolysis after intravenous immune globulin therapy: relation to IgG subclasses of red cell antibody. Transfusion. 30(5):1990;436-438.
25. Shoham-Kessary H., Gershon H. Isoantibodies in immunoglobulin for intravenous use may cause erythrocyte sequestration. Vox Sang. 77(1):1999;33-39.
26. Copelan E.A., Strohm P.L., Kennedy M.S., Tutschka P.J. Hemolysis following intravenous immune globulin therapy. Transfusion. 26:1985;410-412.
27. Moscow J.A., Casper A.J., Kodis C., Fricke W.A. Positive direct antiglobulin test results after intravenous immune globulin administration. Transfusion. 27:1987;248-929.
28. Nydegger U.E., Mohacsi P.J., Escher R., Morell A. Clinical use of intravenous immunoglobulins. Vox Sang. 78(Suppl 2):2000;191-195.
29. Nicholls M.D., Cummins J.C., Davies V.J., Greenwood J.K. Haemolysis induced by intravenously-administered immunoglobulin. Med. J. Aust. 150(7):1989;404-406.
30. Ballot-Brossier C., Mortelecque R., Sinegre M., Marceau A., Dauriat G., Courtois F. Insisting on intravenous polyvalent immunoglobulin therapy in polymyositis in spite of the occurrence of sever hemolytic anemia. Transfus. Clin. Biol. 8(2):2001;94-99.
31. Comenzo R.L., Malachowski M.E., Meissner H.C., Fulton D.R., Berkman E.M. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J. Pediatr. 120(6):1992;926-928.
32. Brox A.G., Cournoyer D., Sternbach M., Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am. J. Med. 82(3 Spec No):1987;633-635.
33. Tamada K., Kohga M., Masuda H., Hattori K. Hemolytic anemia following high-dose intravenous immunoglobulin administration. Acta. Paediatr. Jpn. 37(3):1995;335-391.
34. Shoham-Kessary H., Naot Y., Gershon H. Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes. Clin. Exper. Immunol. 13(1):1998;77-84.
35. Kim H.C., Park C.L., Cowan J.H., Fattori F.D., August C.S. Massive intravascular hemolysis associated with intravenous immunoglobulin in bone marrow transplant recipients. Am. J. Pediatr. Hematology-Oncology. 10(1):1988;69-76.
36. Thomas M.J., Misbah S.A., Chapel H.M., Jones M., Elrington G., Newsom-Davis J. Hemolysis after high-dose intravenous Ig Blood. 82:1993;3789.
37. Nakamura S., Yoshida T., Ohtake S., Matsuda T. Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura. Acta. Haematologica. 76(2-3):1986;115-118.
38. Kessary-Shoham H., Levy Y., Shoenfeld Y., Lorber M., Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J. Autoimmun. 13(1):1999;129-135.
39. Robertson V.M., Dickson L.G., Romond E.H., Ash R.C. Positive antiglobulin tests due to intravenous immunoglobulin in patients who received bone marrow transplant. Transfusion. 27:1987;28-31.
40. Takahashi H., Tsukada T. Triamterene-induced immune haemolytic anaemia with acute intravascular haemolysis and acute renal failure. Scand. J. Haematol. 23(2):1979;169-176.